Robins David C. Acquired Stake in Tetralogic Pharmaceuticals Corp

August 4, 2017 - By Adrian Erickson

 Robins David C. Acquired Stake in Tetralogic Pharmaceuticals Corp

Investors sentiment decreased to 0 in 2016 Q4. Its down 2.50, from 2.5 in 2016Q3. It fall, as 21 investors sold Tetralogic Pharmaceuticals Corp shares while 0 reduced holdings. 0 funds opened positions while 0 raised stakes. 42,450 shares or 95.28% less from 899,530 shares in 2016Q3 were reported.

Moreover, Burt Wealth Advsr has 0% invested in Tetralogic Pharmaceuticals Corp (OTCMKTS:TLOG) for 2,625 shares. Glenmede Trust Na owns 3,925 shares or 0% of their US portfolio. California Pub Employees Retirement owns 35,900 shares or 0% of their US portfolio.

The New Robins David C. Holding in Tetralogic Pharmaceuticals Corp

Robins David C. reported SC 13G form with the SEC for Tetralogic Pharmaceuticals Corp. Access it here: 000121465917004804. As reported by Robins David C., the filler owns 5.85% or 1,450,000 shares of the Health Care–company.

Tetralogic Pharmaceuticals Corp stake is new for [reportingPerson]. Date of activity: August 1, 2017. This shows Robins David C.’s positive view for Tetralogic Pharmaceuticals Corp.

Tetralogic Pharmaceuticals Corp Institutional Sentiment

Filings show 27 investors own Tetralogic Pharmaceuticals Corp. The ownership in Q3 2015 is low, at 24.20 % of the outstanding shares. This is decreased by 301184. 5994401 were owned by these investors. 4 funds opened new Tetralogic Pharmaceuticals Corp stakes, 5 increased positions. There were 9 that closed positions and 3 reduced them.

Burt Wealth Advisors is an investor bullish on Tetralogic Pharmaceuticals Corp, owning 2625 shares as of Q3 2015 for less than 0.01% of its portfolio. J. Carlo Cannell Cannell Peter B & Company Inc owns 11713 shares or less than 0.01% of its portfolio. WA First Washington Corp have 0.36% of its portfolio for 319250 shares. Further, First Eagle Investment Management Llc reported stake worth less than 0.01% of its portfolio. The MA Clarus Ventures Llc owns 4644705 shares. Tetralogic Pharmaceuticals Corp is 4.94% of its portfolio.

Business Profile

TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. The Company’s segment is the identification and development of novel small molecule therapies in oncology and infectious diseases. The Company has approximately two clinical-stage product candidates in development, such as birinapant and SHAPE. SHAPE is the Company’s histone deacetylase (HDAC) inhibitor that it is developing for topical use for the treatment of early-stage cutaneous T-cell lymphoma (CTCL). The Company is also exploring studying SHAPE in alopecia areata, an autoimmune skin disease. SHAPE has been granted the United States orphan drug designation for CTCL. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases (SMAC)-mimetic, which leads to apoptosis or cell-death in damaged cells.

SEC Form 13G.

About 58,535 shares traded or 0.45% up from the average. Tetralogic Pharmaceuticals Corp (OTCMKTS:TLOG) has 0.00% since August 4, 2016 and is . It has underperformed by 16.70% the S&P500.

TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The company has market cap of $606,847. The Firm is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. It currently has negative earnings. The Company’s segment is the identification and development of novel small molecule therapies in oncology and infectious diseases.

More important recent Tetralogic Pharmaceuticals Corp (OTCMKTS:TLOG) news were published by: Bizjournals.com which released: “Malvern biopharm company’s stock plunges after study is stopped” on May 06, 2015, also Quotes.Wsj.com published article titled: “TetraLogic Pharmaceuticals Corp.”, Globenewswire.com published: “TetraLogic Pharmaceuticals Corporation Announces Completion of Sale of SMAC …” on December 29, 2016. More interesting news about Tetralogic Pharmaceuticals Corp (OTCMKTS:TLOG) was released by: Globenewswire.com and their article: “TetraLogic Pharmaceuticals Announces Data on Lead Clinical Programs” with publication date: January 06, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.